In vivo inhibitory effects of puerarin on selected rat cytochrome P450 isoenzymes

Pharmazie

Volumn 69, Issue 5, 2014, Pages 367-370

  Guo, Yu Jin ^a   Liang, Dong Lou ^a   Xu, Zhi Sheng ^b   Ye, Qiang ^b  

^a Shandong Jining No1 People's Hospital   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MIDAZOLAM; PUERARIN; TOLBUTAMIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZATION; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; INDICATORS AND REAGENTS; ISOENZYMES; ISOFLAVONES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84900543036     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.3823     Document Type: Article

References (28)

1. Chen R, Xue J, Xie M (2012) Puerarin prevents isoprenaline-induced myocardial fibrosis in mice by reduction of myocardial TGF-beta1 expression. J Nutr Biochem 23: 1080-1085.
2. Choo MK, Park EK, Yoon HK, Kim DH (2002) Antithrombotic and antiallergic activities of daidzein, a metabolite of puerarin and daidzin produced by human intestinal microflora. Biol Pharm Bull 25: 1328-1332.
3. Danielson PB (2002) The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Current Drug Metabol 3: 561-597.
4. Fasinu PS, Bouic PJ, Rosenkranz B (2012) An overview of the evidence and mechanisms of herb-drug interactions. Frontiers Pharmacol 3: 69.
5. Gao L, Ji X, Song J, Liu P, Yan F, GongW, Dang S, Luo Y (2009) Puerarin protects against ischemic brain injury in a rat model of transient focal ischemia. Neurol Res 31: 402-406.
6. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9: 295-306. (Pubitemid 29376373)
7. He H, Shi M, Yang J, Zeng X, Qiao H, Wu L, Li L (2008) The correlation between angiogenesis and abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure, and improvement by puerarin. Phytother Res 22: 948-956.
8. Huang F, Liu K, Du H, Kou J, Liu B (2012) Puerarin attenuates endothelial insulin resistance through inhibition of inflammatory response in an IKKbeta/IRS-1-dependent manner. Biochimie 94: 1143-1150.
9. IzzoAA (2005) Herb-drug interactions: an overviewof the clinical evidence. Fundament Clin Pharmacol 19: 1-16.
10. Izzo AA, Ernst E (2009) Interactions between herbal medicines and prescribed drugs - an updated systematic review. Drugs 69: 1777-1798.
11. Leung AY (2006) Traditional toxicity documentation of Chinese Materia Medica - an overview. Toxicol Pathol 34: 319-326.
12. Liu CM, Ma JQ, Sun YZ (2011) Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats. Food Chem Toxicol 49: 3119-3127.
13. Liu CM, Ma JQ, Sun YZ (2012) Puerarin protects rat kidney from lead-induced apoptosis by modulating the PI3K/Akt/eNOS pathway. Toxicol Appl Pharmacol 258: 330-342.
14. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82: 667-715.
15. Peyronneau MA, Renaud JP, Jaouen M, Urban P, Cullin C, Pompon D, Mansuy D (1993) Expression in yeast of three allelic cDNAs coding for human liver P-450 3A4. Different stabilities, binding properties and catalytic activities of the yeast-produced enzymes. Eur J Biochem FEBS 218: 355-361. (Pubitemid 24003748)
16. Saxena A, Tripathi KP, Roy S, Khan F, Sharma A (2008) Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. Bioinformation 3:198-204.
17. Schwarz UI (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33 Suppl 2:23-30.
18. Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nature Rev Cancer 6: 546-558. (Pubitemid 43980543)
19. Stresser DM, Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metabol Dispos 27: 517-525. (Pubitemid 29177646)
20. Sui Y, Zhao HL, Wong VC, Brown N, Li XL, Kwan AK, Hui HL, Ziea ET, Chan JC (2012) A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. Obesity Rev 13: 409-430.
21. Wang J, ZouW(2011) Practices, challenges, and opportunities: HIV/AIDS treatment with traditional Chinese medicine in China. Frontiers Med 5: 123-126.
22. Wong KH, Li GQ, Li KM, Razmovski-Naumovski V, Chan K (2011) Kudzu root: traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases. J Ethnopharmacol 134: 584-607.
23. Xu W, Towers AD, Li P, Collet JP (2006) Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China. Eur J Cancer Care 15: 397-403. (Pubitemid 44359404)
24. Yao XJ, Yin JA, Xia YF, Wei ZF, Luo YB, Liu M, Feleder C, Dai Y (2012) Puerarin exerts antipyretic effect on lipopolysaccharide-induced fever in rats involving inhibition of pyrogen production from macrophages. J Ethnopharmacol 141: 322-330.
25. Youns M, Hoheisel JD, Efferth T (2010) Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine. Planta Med 76: 2019-2025.
26. Yu C, Chai X, Yu L, Chen S, Zeng S (2011) Identification of novel pregnane X receptor activators from traditional Chinese medicines. J Ethnopharmacol 136: 137-143.
27. Zhang H, Zhang L, Zhang Q, Yang X, Yu J, Shun S, Wu Y, Zeng Q, Wang T (2011) Puerarin: a novel antagonist to inward rectifier potassium channel (IK1). Mol Cell Biochem 352: 117-123.
28. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41: 89-295.